IASLC World Conference on Lung Cancer 2021

At the IASLC WCLC 2021 virtual meeting, Boehringer Ingelheim presented the latest updates on the afatinib* real world data in advanced non-small cell lung cancer (NSCLC).


Please see below for more information and a downloadable version of the publication.


Virtual exhibit


Click here to view our latest virtual exhibit.


Wednesday 8 September – Tuesday 14 September, 2021
Virtual format

Product theater showcase

Thinking Beyond KRAS G12C Inhibition in NSCLC

Watch as our experts – Victoria Zazulina, Darryl McConnell, and Kristie Fernamberg –  engage in a roundtable discussion about KRAS-mutant NSCLC and recent advances in the treatment of this disease. The discussion includes conversation on Boehringer Ingelheim’s approach for targeting mutations beyond KRAS G12C.


Pushing Checkpoint Inhibition Beyond PD-1

Our experts – Victoria Zazulina, Michael Merger, and Sophia Valai –present emerging immuno-oncology strategies for treating NSCLC, highlighting combinations of PD-1 checkpoint inhibition with STING agonism, VEGF/Ang2 inhibition, SIRPα and MDM2-p53 antagonism, as well as the potential role of oncolytic viruses and T-cell engagers in immune-oncology therapy.



Browse through the publications below to learn more about our latest clinical trials with afatinib.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Wednesday 8 September – Tuesday 14 September, 2021
A real-world cohort study of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations (UpSwinG)
Author(s): Miura et al.
Tumor Type(s): non-small cell lung cancer (NSCLC)
Abstract Number: 367
Sequential afatinib and osimertinib in patients with advanced EGFRm+ NSCLC and acquired T790M: the real-world UpSwinG study
Author(s): Popat et al.
Tumor Type(s): non-small cell lung cancer (NSCLC)
Abstract Number: 374
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.


*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.


© 2021 Boehringer Ingelheim International GmbH. All rights reserved.


Page last updated: September 2021